The effect of CRP level on predicting BCa prognosis was analysed based on the combined HRs and 95%CIs. The Cochrane Q test and I2 statistics were used to assess among-study heterogeneity. p < .10 or I2 >50% was identified as indicators of significant heterogeneity, so a random-effects model should be adopted; otherwise, a fixed-effects model should be applied. We also conducted subgroup analyses based on various clinical factors for further investigation. The relationship between CRP and BCa clinicopathological factors was investigated by combining the odds ratios (ORs) with 95%CIs. Publication bias was assessed using Begg’s and Egger’s tests. Stata version 12.0 software (Stata Corp., College Station, TX) was used for the statistical analysis. Statistical significance was set at p < .05.
Stata version 12
Manufactured by StataCorp
Sourced in United States, United Kingdom, Denmark, Austria, Spain, Canada, Israel, Belgium
About the product
Stata version 12 is a comprehensive, integrated statistical software package developed by StataCorp. It provides a wide range of data management, statistical analysis, and graphics capabilities. Stata version 12 is designed to handle complex data structures and offers a variety of statistical models and methods for researchers and analysts.
Automatically generated - may contain errors
Lab products found in correlation
Spss version 20, by IBM (28 mentions)
Spss version 22, by IBM (17 mentions)
Stata 12, by StataCorp (17 mentions)
Spss version 21, by IBM (15 mentions)
Stata, by StataCorp (15 mentions)
Spss version 19, by IBM (13 mentions)
Prism 5, by GraphPad (10 mentions)
Prism 6, by GraphPad (10 mentions)
Spss version 23, by IBM (8 mentions)
Stata statistical software release 12, by StataCorp (8 mentions)
Spss version 18, by IBM (8 mentions)
Spss 22, by IBM (7 mentions)
Prism 7, by GraphPad (6 mentions)
Spss for windows version 20, by IBM (5 mentions)
Spss version 17, by IBM (5 mentions)
Enterprise guide 7, by SAS Institute (5 mentions)
Prism version 6, by GraphPad (4 mentions)
Spss statistics version 20, by IBM (4 mentions)
Open meta analyst software, by Tufts University (4 mentions)
Spss 20, by IBM (4 mentions)
Check compatibility
Market Availability & Pricing
Stata version 12 is no longer actively commercialized by StataCorp. While it is not explicitly marked as discontinued, it is absent from the company's current product listings and official sales channels. Consequently, official pricing is unavailable. However, second-hand copies may be found on various online marketplaces, with prices typically ranging from $50 to $200, depending on the condition and included materials.
Need Operating Instructions, SDS, or distributor details? Just ask our AI Agent.
Is this product still available?
Get pricing insights and sourcing optionsSimilar products (other manufacturers)
Stata version 12 (by IBM) - 22 citations
Stata version 12 (by SAS Institute) - 20 citations
STATA version 12.0 (by StataCrop) - 6 citations
Stata version 12 (by GraphPad) - 4 citations
Stata (version 12, Manufacturer, (by Manufacturer) - 3 citations
Stata, version 12 (by R Project for Statistical Computing) - 2 citations
Stata version 12.0 (by StataCop) - 2 citations
STATA version 12.1 (by TestCorp) - 2 citations
Stata version 12 (by StatCorporation) - 2 citations
The spelling variants listed below correspond to different ways the product may be referred to in scientific literature.
These variants have been automatically detected by our extraction engine, which groups similar formulations based on semantic similarity.
Product FAQ
5 552 protocols using «stata version 12»
1
CRP Predicts Bladder Cancer Prognosis
2
Survival Analysis of Participant Outcomes
Data analysis was performed using STATA® version 12.0, Stata Corp, College Station, Texas USA. Quantitative variables were described as medians with their interquartile range (IQR), and categorical variables were presented as proportions. Chi-square (X2) or Fisher’s exact tests were used to compare proportions. The Kaplan-Meier survival curve was used to estimate mortality and LTFU probability among the participants. Variables were statistically significant when the p value < 0.05.
3
Prognostic Value of CONUT in DLBCL
Pooled HRs with 95%CIs were analyzed to assess the prognostic value of CONUT for DLBCL. The between-study heterogeneity was assessed using the I2 statistics as well as Cochran’s Q-test. I2 > 50% or a p-value < 0.10 (Q-test) indicates obvious heterogeneity, in which case a random-effects model was utilized; otherwise, the fixed-effects model was selected. Subgroup analyses were performed to investigate the prognostic value of CONUT in different DLBCL population groups. The relation of CONUT with patient clinicopathological factors was assessed through pooled odds ratios (ORs) with 95%CIs. Sensitivity analysis was performed by eliminating one article and calculating new HRs to assess their robustness and stability. We further adopted Funnel plot, Begg’s and Egger’s tests to evaluate publication bias in the enrolled articles. Further, we employed Stata version 12.0 software (Stata Corp, College Station, Texas, USA) in statistical analysis. Statistical significance was set at P < 0.05.
4
Acetabular Cup Positioning Accuracy
The study parameters included patient demographics, acetabular cup type, operative time, blood loss, dislocation, and infection. The primary outcome was the percentage of cups within 5° of the target position (RI/RA 40°/20° ± 5°), chosen to match computer navigation precision (4.4° inclination, 4.1° anteversion) [13 (link)]. Secondary outcomes were the percentage within the Grammatopoulos zone (RI/RA 40°/20° ± 10°). The intra-class correlation coefficients (ICCs) assessed intra-/inter-observer reliability using a two-way random-effects model. Categorical data were compared using the exact probability test, and continuous data with the t-test, with p < 0.05 statistically significant. Analyses used STATA version 12.1 (StataCorp LLC, USA).
The sample size calculation aimed to detect a difference in the percentage of cups positioned within 5° of the target between two placement methods. A prior study found the MAG method achieved this in 45% of hips [14 (link)]. We hypothesized our novel method could reach 80%, similar to computer navigation [13 (link), 15 (link), 16 ]. Using the two-independent-proportions formula [17 ], with a 0.01 error level, 90% power, and a 2:1 ratio, we calculated 80 cases for the study group and 40 for the control group. The study received ethical approval (Code 143/63) and was registered (ID: TCTR20201220001).
The sample size calculation aimed to detect a difference in the percentage of cups positioned within 5° of the target between two placement methods. A prior study found the MAG method achieved this in 45% of hips [14 (link)]. We hypothesized our novel method could reach 80%, similar to computer navigation [13 (link), 15 (link), 16 ]. Using the two-independent-proportions formula [17 ], with a 0.01 error level, 90% power, and a 2:1 ratio, we calculated 80 cases for the study group and 40 for the control group. The study received ethical approval (Code 143/63) and was registered (ID: TCTR20201220001).
5
Nurses' Knowledge, Attitudes, and Involvement in Legal Issues
Data were summarized and reported with frequency and percentage for qualitative variables. Quantitative variables were presented with mean and standard deviations. The data were weighted to the population and standardized according to WHO population estimates for 2000–2025 using survey analysis. The relationships between nurses' knowledge, attitudes, and involvement in legal issues were assessed using Pearson's correlation coefficient. The adjusted association between these variables and other confounding factors was evaluated using multiple linear regression analysis. Data analysis was performed using Stata version 12 (StataCorp LLC, College Station, TX), with significance levels considered at p < 0.001.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!
Request a quote
🧪 Need help with an experiment or choosing lab equipment?
I search the PubCompare platform for you—tapping into 40+ million protocols to bring you relevant answers from scientific literature and vendor data.
I search the PubCompare platform for you—tapping into 40+ million protocols to bring you relevant answers from scientific literature and vendor data.
1. Find protocols
2. Find best products for an experiment
3. Validate product use from papers
4. Check Product Compatibility
5. Ask a technical question
Want to copy this response? Upgrade to Premium to unlock copy/paste and export options.